Earum Pharmaceuticals Ltd (BSE: 542724) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹0 Cr, it ranks #5,323 by market cap among the 6,197 Indian listed companies on FinBizNet, and #61 of 63 in Pharmaceuticals. At ₹0.19 (as of 16 Nov 2026), the share price is 74.0% below its 52-week high of ₹0.73 and 0.0% above its 52-week low of ₹0.19. The share price is down 70.3% over one year and up 0.0% over three months.
| Current Price | ₹0.19 |
|---|---|
| Market Cap | ₹0 Cr |
| BSE Code | 542724 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 4.8 |
| Return on Equity | 5.69% |
| Return on Assets | 1.63% |
| 52-Week Range | ₹0.19 – ₹0.73 |
| 1-Year Price Change | -70.3% |
| 3-Month Price Change | 0.0% |
| Beta (1Y) | 0.05 |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.earumpharma.com |
| Revenue | ₹0 Cr |
|---|---|
| Net Profit | ₹-0 Cr |
| Net Margin | -104.3% |
| EPS (Basic) | ₹0.00 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Murae Organisor Limited engages in the trade in agriculture activities in India. The company was formerly known as Earum Pharmaceuticals Limited and changed its name to Murae Organisor Limited in November 2023. Murae Organisor Limited was incorporated in 2012 and is based in Ahmedabad, India.
1. Pharmaceuticals Intermediates-This segment engages in the manufacture, marketing, trading, and distribution of a range of pharmaceutical formulation products.
1. Trading in Agriculture Activities-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Earum Pharmaceuticals Ltd | ₹0 Cr | 4.8 | 5.69% | ₹0 Cr | -70.3% |
Listed by market capitalisation. Ratios are shown for context only.
Earum Pharmaceuticals Ltd is trading at ₹0.19, with a market capitalisation of ₹0 Cr.
Earum Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Earum Pharmaceuticals Ltd has a P/E of 4.8 and a return on equity of 5.69%.
Earum Pharmaceuticals Ltd is listed on the BSE under the scrip code 542724.
Earum Pharmaceuticals Ltd's share price is down 70.3% over one year and up 0.0% over three months. Its 52-week range is ₹0.19 to ₹0.73.
In Q1 FY26, Earum Pharmaceuticals Ltd reported revenue of ₹0 Cr and net profit of ₹-0 Cr, with basic EPS of ₹0 (standalone, parsed from the company's exchange filing).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.